TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).
Neuren Pharmaceuticals Limited has announced the quotation of 100,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of August 28, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing projects, potentially impacting its market position and providing opportunities for stakeholders.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$22.00 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is known for its research and development of treatments aimed at addressing unmet medical needs in the neurology sector.
Average Trading Volume: 503,793
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$2.25B
Learn more about NEU stock on TipRanks’ Stock Analysis page.